MA52458A - Nouvelles formes cristallines - Google Patents

Nouvelles formes cristallines

Info

Publication number
MA52458A
MA52458A MA052458A MA52458A MA52458A MA 52458 A MA52458 A MA 52458A MA 052458 A MA052458 A MA 052458A MA 52458 A MA52458 A MA 52458A MA 52458 A MA52458 A MA 52458A
Authority
MA
Morocco
Prior art keywords
crystalline forms
new crystalline
new
forms
crystalline
Prior art date
Application number
MA052458A
Other languages
English (en)
Inventor
Nishanth Gopinathan
Erwin Irdam
William KIESMAN
Daw-Long Albert Kwok
Yiqing Lin
Frederick Osei-Yeboah
Matthew Peterson
Kenny Tran
Kalyan Vasudevan
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA52458A publication Critical patent/MA52458A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
MA052458A 2017-05-19 2018-05-18 Nouvelles formes cristallines MA52458A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508830P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
MA52458A true MA52458A (fr) 2021-03-10

Family

ID=64274700

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052458A MA52458A (fr) 2017-05-19 2018-05-18 Nouvelles formes cristallines

Country Status (10)

Country Link
US (2) US20200062705A1 (fr)
EP (1) EP3634400A4 (fr)
JP (1) JP2020520933A (fr)
KR (1) KR20200007831A (fr)
CN (1) CN110913852A (fr)
AU (1) AU2018269924B2 (fr)
CA (1) CA3062884A1 (fr)
MA (1) MA52458A (fr)
MX (2) MX2019013758A (fr)
WO (1) WO2018213686A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1943216B1 (fr) * 2005-10-10 2010-06-30 Glaxo Group Limited Dérivés de prolinamide en tant que modulateurs des canaux sodiques
EP2117538A1 (fr) * 2007-01-24 2009-11-18 Glaxo Group Limited Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-)
DK2477964T5 (en) * 2009-09-14 2015-05-26 Convergence Pharmaceuticals A process for the preparation of alpha-carboxamide
ES2912881T3 (es) * 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina

Also Published As

Publication number Publication date
US20200062705A1 (en) 2020-02-27
AU2018269924A1 (en) 2019-11-14
MX2023003297A (es) 2023-04-13
CN110913852A (zh) 2020-03-24
CA3062884A1 (fr) 2018-11-22
MX2019013758A (es) 2020-07-20
AU2018269924B2 (en) 2022-07-07
KR20200007831A (ko) 2020-01-22
EP3634400A4 (fr) 2021-06-09
EP3634400A1 (fr) 2020-04-15
JP2020520933A (ja) 2020-07-16
WO2018213686A1 (fr) 2018-11-22
US20220098150A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
MA51819A (fr) Nouvelles formes cristallines
FIC20253006I1 (fi) Linvoseltamabi
FIC20260010I1 (fi) imlunestrantti
EP3890716A4 (fr) Polythérapies
EP3846674C0 (fr) Spéculum vaginal
EP3849534A4 (fr) Polythérapies
EP3555124C0 (fr) Tcr nyeso
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
LT3978483T (lt) Kristalinis (s)-afoksolanerio tolueno solvatas
MA47596A (fr) Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan
EP3781060A4 (fr) Cryosonde
DK3829402T3 (da) Tæppe
DK3387930T3 (da) Stofanordning
EP3784463A4 (fr) Fluorosulfones
EP3872558A4 (fr) Optoisolateur
MA50913A (fr) Nouvelles combinaisons de défoliants
EP3810860C0 (fr) Coupleur
EP3792200A4 (fr) Conteneur-citerne
EP3745904C0 (fr) Poignée de bâton
MA46567A (fr) Formes cristallines de l'éravacycline
EP3878374A4 (fr) Dispositif d'occlusion
EP3721129A4 (fr) Cryosphère
EP3645102A4 (fr) Timbre transdermique à rappel automatique
MA46266A (fr) Formes cristallines
LT3668879T (lt) Nauji junginiai